Intraductal cribriform breast adenocarcinoma

Summary

Intraductal cribriform breast adenocarcinoma (MONDO:0045060) is a disease. A subtype of ductal breast carcinoma in situ — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intraductal cribriform breast adenocarcinoma
Mondo ID	MONDO:0045060
NCIT	C5138
UMLS	C1334248
MedGen	233570
Is cancer (heuristic)	no

Also known as: cribriform DCIS of breast · cribriform DCIS of the breast · cribriform ductal breast carcinoma in situ · cribriform ductal carcinoma in situ of breast · cribriform ductal carcinoma in situ of the breast · DCIS of breast with cribriform pattern · DCIS of the breast with cribriform pattern · ductal carcinoma in situ of breast with cribriform pattern · ductal carcinoma in situ of the breast with cribriform pattern · intraductal cribriform breast adenocarcinoma · non-infiltrating cribriform ductal breast carcinoma · non-invasive cribriform ductal breast carcinoma

Disease family

This is a subtype of ductal breast carcinoma in situ. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › adenocarcinoma in situ › ductal breast carcinoma in situ › intraductal cribriform breast adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.